机构：[1]Department of Anesthesiology, the Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, China.[2]Hebei Provincial Cancer Institute, Shijiazhuang, Hebei 050011, China.临床科室河北省肿瘤研究所河北医科大学第四医院[3]Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei 050021, China.
出处：
ISSN：
摘要：
Myeloid-derived suppressor cells (MDSCs) are immature suppressive cells partly influencing the efficacy of cancer immunotherapies. The crosstalk between MDSCs and immune cells mediates a potently immunosuppressive network within the tumor microenvironment to attenuate the anti-tumor response. Targeting MDSCs could be a potential therapeutic approach to overcome the limitation of immunotherapies. In this article, we will review available information on how MDSCs exert their immunosuppressive function and summarize the therapeutic strategies targeting them to enhance the efficacy of cancer immunotherapies.
语种：
外文
PubmedID：
中科院分区：
出版当年[2020]版：
大类|4 区医学
小类|4 区医学：研究与实验
最新[2025]版：
大类|4 区医学
小类|4 区医学：研究与实验
第一作者：
第一作者机构：[1]Department of Anesthesiology, the Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Huo Shuping,Liu Liang,Li Qiaomin,et al.Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy[J].Discovery Medicine.2020,30(161):119-128.
APA：
Huo Shuping,Liu Liang,Li Qiaomin&Wang Jing.(2020).Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.Discovery Medicine,30,(161)
MLA：
Huo Shuping,et al."Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy".Discovery Medicine 30..161(2020):119-128
